For instance, mTOR inhibitors have been shown to inhibit hypoxia- or growth factor-induced endothelial cell proliferation, migration, and tube formation in in vitro studies.24 Likewise, the antiangiogenic efficacy of mTOR inhibitors have been validated in a variety of cancer models in vivo.25–28 Inhibition of mTOR induces apoptosis in tumor-associated endothelial cells that ultimately leads to significant reductions in microvessel density and tumor growth. This evidence concerns the gene MTOR and cancer.